ClinicalTrials.gg
CompletedNCT02252965CONSENTUpdated Jan 24, 2017Results posted

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes

A Phase 4 interventional study of Metformin IR and Metformin XR in Diabetes Mellitus, Type 2, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-01-24.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
40th of 287
532 · median 100
Started
2014
with 15 others
Phase 4
98 of 293
6 open now
Registered
195th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 40th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 98 in phase 4, and was the 195th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability and efficacy in the newly diagnosed subjects with Type 2 diabetes who have glycosylated hemoglobin (HbA1c) value between 7.0 to 10.0 percent (%).

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes Mellitus, Type 2
  • Metformin XR
  • Metformin IR
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Type 2 diabetes mellitus before the screening visit based on the World Health Organization (WHO) diagnostic and classification criteria
  • value of 7.0-10.0%, inclusive
  • Age ranging from 18 to 79 years, inclusive
  • Treatment-naive for oral antidiabetic agents (that is, had not received antidiabetic medication previously, or had received antidiabetic medication for at least 14 days and not within 1 month of enrolment)
  • Male, or non-pregnant, non-breastfeeding females
  • (BMI) greater than or equal to (>=) 18.5 and less than (\<) 35 kilogram per square meter (kg/m\^2)
  • In the opinion of the investigator, subjects are well-motivated, capable and willing to continue the study treatment as required during the whole study period, maintain a study dietary, as required for this protocol, attend scheduled visits and be willing to receive phone calls between visits, avoid pregnancy by using an adequate method of throughout the duration of the study for the female subjects of child bearing potential (and if appropriate male subjects with female partners of )
  • Written given before any trial-related activities are carried out

Exclusion criteria

Exclusion criteria:

  • Type 1 diabetes
  • Previous treatment with insulin or other antidiabetics (including Chinese traditional medicine) for more than 14 days continuously or within 1 month of enrolment
  • Any of the protocol-specified cardiovascular conditions within 3 months prior to the screening visit
  • Impaired liver function as defined in the protocol
  • Serum creatinine values as specified in the protocol
  • Known proliferative retinopathy or maculopathy requiring acute treatment, or recurrent major hypoglycemia or hypoglycemic unawareness as judged by the investigator
  • Persistent uncontrolled hypertension
  • Severe chronic gastrointestinal disease
  • Previous history of 1 or more episodes of ketoacidosis or hyperosmolar state/coma
  • Currently receiving chronic (>14 days) systemic therapy (excluding topical, intraocular, inhaled or intranasal preparations) or have received such therapy within 4 weeks of the screening visit
  • Current use of beta-blockers, thiazide diuretic, thyroid products, estrogens, oral , phenytoin, nicotinic acid, sympathomimetics, nifedipine and isoniazid and cannot be replaced by any other treatment
  • Have any hematologic condition that may interfere with measurement (for example, hemolytic anemia, sickle-cell disease)
  • Have any other condition (such as, known drug or alcohol abuse or a psychiatric disorder) that may prevent the subject from following and completing the protocol
  • Known to Metformin Hydrochloride
  • Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Any to Metformin according to local package insert
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
532 participants (actual)

Study arms

  • Active comparator
    Metformin IR

    Drug: Metformin IR

  • Experimental
    Metformin XR

    Drug: Metformin XR

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.

    Also known as: Glucophage IR

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.

    Also known as: Glucophage XR

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16

    Time frame: Baseline, Week 16

  2. Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period

    An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Baseline up to Week 16

Secondary outcomes

  1. Percentage of Subjects With Pre-specified Gastrointestinal Adverse Events During Treatment Period

    An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Number of subjects with pre-specified gastrointestinal adverse events (diarrhea, nausea, abdominal pain, bloating, constipation, dyspepsia and flatulence) were reported.

    Time frame: Baseline up to Week 16

  2. Change From Baseline in Fasting Plasma Glucose (FPG) Level at Week 1, 2, 4, 8, 12 and 16

    Time frame: Baseline, Week 1, 2, 4, 8, 12,16

  3. Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) Level at Weeks 8 and 16

    The 2-hour Postprandial plasma glucose (PPG) level refers to the plasma glucose concentrations after 2 hours of eating.

    Time frame: Baseline, Week 8 and 16

  4. Percentage of Subjects With Hypoglycemia

    Hypoglycemia, also called as low blood glucose or low blood sugar, is defined as the blood glucose level of less than normal (that is less than 3.9 millimole per liter \[mmol/L\]).

    Time frame: Baseline up to Week 16

  5. Percentage of Subjects With Marked Hyperglycemia

    Marked hyperglycemia was defined as the FPG level of greater than or equal to 11.1 mmol/L.

    Time frame: Baseline up to Week 16

  6. Percentage of Subjects With HbA1c Less Than (<) 7%

    Time frame: Baseline up to Week 16

  7. Percentage of Subjects Who Are Totally Intolerant to the Treatment

    Subjects were considered to be totally intolerant if they experienced a Grade 3 or higher toxicity considered at least possibly related to the treatment.

    Time frame: Baseline up to Week 16

  8. Percentage of Subjects With HbA1c Less Than (<) 7% and With no Severe Gastrointestinal (GI) and Other Adverse Events (AEs)

    Percentage of subjects with HbA1c \<7% and with no severe GI and other AEs were reported. Severe adverse events were based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 and were defined as those events which were medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL). Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

    Time frame: Baseline up to Week 16

  9. Percentage of Subjects Who Are Compliant to Treatment

    Compliance was defined as not skipping or forgetting dosing or not delaying the dosing time. Subjects who never missed a dose of medication were considered compliant.

    Time frame: Baseline up to Week 16

07

Results

Posted Jan 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneMetformin IRMetformin XR
Started267265
Safety population261264
Completed227222
Not completed4043
Withdrew: Adverse event914
Withdrew: Lost to follow-up168
Withdrew: Protocol violation45
Withdrew: Lack of efficacy02
Withdrew: Withdrawal by subject79
Withdrew: Other45

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16
Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16
Percentage of HbA1cMetformin IRMetformin XR
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16-1.61 ± 0.05-1.58 ± 0.05
Statistical analysis
  • Metformin IR vs Metformin XR · Least squares (ls) mean difference: 0.03 · 95% CI -0.10 to 0.17
PrimaryOverall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period

An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period
percentage of subjectsMetformin IRMetformin XR
Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period23.8 (18.72 to 29.39)22.3 (17.47 to 27.86)
Statistical analysis
  • Metformin IR vs Metformin XR · Mantel Haenszel · p = 0.674 · Percentage difference: -1.52 · 95% CI -8.60 to 5.56
SecondaryPercentage of Subjects With Pre-specified Gastrointestinal Adverse Events During Treatment Period

An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Number of subjects with pre-specified gastrointestinal adverse events (diarrhea, nausea, abdominal pain, bloating, constipation, dyspepsia and flatulence) were reported.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects With Pre-specified Gastrointestinal Adverse Events During Treatment Period
percentage of subjectsMetformin IRMetformin XR
Diarrhoea16.5 (12.19 to 21.54)12.5 (8.76 to 17.10)
Abdominal Distension6.1 (3.54 to 9.76)6.4 (3.80 to 10.11)
Nausea6.1 (3.54 to 9.76)4.5 (2.37 to 7.81)
Abdominal Pain2.3 (0.85 to 4.94)1.9 (0.62 to 4.36)
Constipation1.9 (0.62 to 4.41)1.9 (0.62 to 4.36)
Dyspepsia1.1 (0.24 to 3.32)0.8 (0.09 to 2.71)
Flatulence0.4 (0.01 to 2.12)0 (0.00 to 1.39)
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) Level at Week 1, 2, 4, 8, 12 and 16
Time frame:
Baseline, Week 1, 2, 4, 8, 12,16
Reported as:
Mean · Millimole Per Liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) Level at Week 1, 2, 4, 8, 12 and 16
Millimole Per Liter (mmol/L)Metformin IRMetformin XR
Baseline (n=251, 254)8.464 ± 1.74708.690 ± 2.0977
Change at Week 1 (n= 249, 248)-0.647 ± 1.5615-0.736 ± 1.4305
Change at Week 2 (n= 243, 244)-1.324 ± 1.4426-1.267 ± 1.9346
Change at Week 4 (n= 240, 239)-1.558 ± 1.6245-1.604 ± 1.7971
Change at Week 8 (n= 219, 230)-2.075 ± 1.7359-1.999 ± 2.0192
Change at Week 12 (n= 216, 221)-2.053 ± 1.7599-2.048 ± 1.8532
Change at Week 16 (n= 214, 218)-1.976 ± 1.7529-2.183 ± 1.8481
SecondaryChange From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) Level at Weeks 8 and 16

The 2-hour Postprandial plasma glucose (PPG) level refers to the plasma glucose concentrations after 2 hours of eating.

Time frame:
Baseline, Week 8 and 16
Reported as:
Mean · mmol/L
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) Level at Weeks 8 and 16
mmol/LMetformin IRMetformin XR
Baseline (n= 223, 231)14.604 ± 3.433414.764 ± 3.7705
Change at Week 8 (n= 215, 229)-3.608 ± 3.6964-3.264 ± 5.9134
Change at Week 16 (n= 213, 215)-3.642 ± 3.7261-3.693 ± 3.5414
SecondaryPercentage of Subjects With Hypoglycemia

Hypoglycemia, also called as low blood glucose or low blood sugar, is defined as the blood glucose level of less than normal (that is less than 3.9 millimole per liter \[mmol/L\]).

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects With Hypoglycemia
percentage of subjectsMetformin IRMetformin XR
Percentage of Subjects With Hypoglycemia1.1 (0.24 to 3.32)3.0 (1.32 to 5.88)
SecondaryPercentage of Subjects With Marked Hyperglycemia

Marked hyperglycemia was defined as the FPG level of greater than or equal to 11.1 mmol/L.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects With Marked Hyperglycemia
percentage of subjectsMetformin IRMetformin XR
Percentage of Subjects With Marked Hyperglycemia0.7 (0.09 to 2.68)2.3 (0.84 to 4.86)
SecondaryPercentage of Subjects With HbA1c Less Than (<) 7%
Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects With HbA1c Less Than (<) 7%
percentage of subjectsMetformin IRMetformin XR
Percentage of Subjects With HbA1c Less Than (<) 7%68.5 (62.60 to 74.06)69.8 (63.90 to 75.28)
SecondaryPercentage of Subjects Who Are Totally Intolerant to the Treatment

Subjects were considered to be totally intolerant if they experienced a Grade 3 or higher toxicity considered at least possibly related to the treatment.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Are Totally Intolerant to the Treatment
percentage of subjectsMetformin IRMetformin XR
Percentage of Subjects Who Are Totally Intolerant to the Treatment7.3 (4.44 to 11.13)5.7 (3.21 to 9.20)
SecondaryPercentage of Subjects With HbA1c Less Than (<) 7% and With no Severe Gastrointestinal (GI) and Other Adverse Events (AEs)

Percentage of subjects with HbA1c \<7% and with no severe GI and other AEs were reported. Severe adverse events were based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 and were defined as those events which were medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL). Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects With HbA1c Less Than (<) 7% and With no Severe Gastrointestinal (GI) and Other Adverse Events (AEs)
percentage of subjectsMetformin IRMetformin XR
Percentage of Subjects With HbA1c Less Than (<) 7% and With no Severe Gastrointestinal (GI) and Other Adverse Events (AEs)68.2 (62.21 to 73.71)69.8 (63.90 to 75.28)
SecondaryPercentage of Subjects Who Are Compliant to Treatment

Compliance was defined as not skipping or forgetting dosing or not delaying the dosing time. Subjects who never missed a dose of medication were considered compliant.

Time frame:
Baseline up to Week 16
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Are Compliant to Treatment
percentage of subjectsMetformin IRMetformin XR
Percentage of Subjects Who Are Compliant to Treatment99.299.2

Adverse events

Collected over Baseline up to Week 18. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin IR—6/249 (2.4%)96/249 (38.6%)
Metformin XR—2/264 (0.8%)136/264 (51.5%)
Metformin IR to XR—0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventMetformin IRMetformin XRMetformin IR to XR
Cardiac failure chronicCardiac disorders1/2490/2640/12
Retinal detachmentEye disorders1/2490/2640/12
Liver injuryHepatobiliary disorders1/2490/2640/12
Foot fractureInjury, poisoning and procedural complications1/2490/2640/12
Adrenal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2490/2640/12
Haemangioma of liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2490/2640/12
Blood glucose increasedInvestigations0/2491/2640/12
Blood ketone body increasedInvestigations0/2491/2640/12
Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2491/2640/12
Most frequent other events
Showing 10 of 117
Most frequent other events
EventMetformin IRMetformin XRMetformin IR to XR
DiarrhoeaGastrointestinal disorders34/24933/2649/12
NauseaGastrointestinal disorders14/24912/2643/12
Muscular WeaknessMusculoskeletal and connective tissue disorders1/2491/2643/12
Abdominal PainGastrointestinal disorders5/2495/2641/12
Abdominal Pain UpperGastrointestinal disorders6/2499/2641/12
Abnormal FaecesGastrointestinal disorders0/2493/2641/12
DyspepsiaGastrointestinal disorders2/2492/2641/12
Urinary tract InfectionInfections and infestations3/2499/2641/12
Muscle InjuryInjury, poisoning and procedural complications0/2490/2641/12
Blood pressure DecreasedInvestigations0/2490/2641/12

Baseline characteristics

Intent to Treat (ITT) population included all subjects who were randomly allocated to a treatment based on the intention to treat

Age, Continuous
Age, Continuous(years)Metformin IRMetformin XRTotal
Mean54.4 ± 10.2153.1 ± 9.7253.8 ± 9.98
Gender
Gender(Participants)Metformin IRMetformin XRTotal
Female112108220
Male155157312
08

Study locations

1 site
  • Please contact the Merck KGaA Communication Center
    Darmstadt, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Nov 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2014
First posted
Sep 30, 2014
Start
Dec 2014
Primary completionActual
Nov 2015
CompletionActual
Apr 2016
Results first posted
Jan 24, 2017
Last update
Jan 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02252965
Responsible party
Sponsor
First posted
Sep 30, 2014
Start date
Dec 2014
Primary completion
Nov 2015
Completion
Apr 2016
Results posted
Jan 24, 2017
Last update
Jan 24, 2017

Study contacts

Medical Responsible
study director · Merck Serono Co., Ltd., Beijing, China

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion